Drug intelligence / Profile preview

HL257

Development stage: Preclinical
Lead developer: HuniLife Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

HL257 is a proprietary monoclonal antibody developed by HuniLife Biotechnology for ophthalmology applications. It targets the enzyme alpha-enolase (ENO1) and has demonstrated promising anti-angiogenesis activity in various in vitro and ex vivo assays. HL257 is being investigated for its therapeutic potential in angiogenesis-driven eye diseases, specifically wet age-related macular degeneration (AMD) and diabetic macular edema (DME). As of June 2025, HL257 remains an early preclinical stage asset with ongoing in vivo studies to validate its efficacy[8].

Targets

ENO (Alpha-enolase)

Beyond the preview

Go deeper on HL257.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL257.

Explore the full profile